How to Get Trulicity (Dulaglutide) in New York

What Is Trulicity and Why Is It Prescribed?

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist manufactured by Eli Lilly, approved by the FDA for adults with type 2 diabetes who need better glycemic control beyond diet and exercise. It works by mimicking the incretin hormone GLP-1, which stimulates glucose-dependent insulin secretion and suppresses glucagon release.

The drug carries a cardiovascular benefit label. The REWIND trial (N=9,901) followed patients with type 2 diabetes for a median of 5.4 years and demonstrated a 12% relative reduction in major adverse cardiovascular events (MACE) with dulaglutide 1.5 mg versus placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026). This makes Trulicity one of only a few GLP-1 RAs with confirmed MACE reduction in a population that included patients both with and without established cardiovascular disease.

New York clinicians prescribe Trulicity across four pen doses: 0.75 mg (starting dose), 1.5 mg, 3.0 mg, and 4.5 mg. Dose titration typically occurs at 4-week intervals based on HbA1c response and tolerability. The American Diabetes Association Standards of Care (2024) recommend GLP-1 RAs as second-line therapy after metformin, or as first-line injectable therapy for patients with established atherosclerotic cardiovascular disease.

New York Telehealth Prescribing Rules for GLP-1 Medications

New York State allows licensed prescribers to initiate and manage Trulicity prescriptions via telehealth. A prescriber must hold an active New York license, establish a genuine provider-patient relationship (which can be done through a synchronous audio-video visit), and document the clinical rationale for GLP-1 RA therapy.

The New York State Education Department Office of the Professions oversees prescriber licensing for MDs, DOs, NPs, and PAs. Nurse practitioners in New York gained full practice authority in 2023, meaning NPs can prescribe Trulicity independently without a collaborative practice agreement. PAs may also prescribe under their supervising physician's protocols.

Several telehealth platforms now serve New York patients seeking GLP-1 RA prescriptions. A typical workflow looks like this:

1. Complete an online intake form with your medical history, current medications, and diabetes diagnosis
2. Upload or share recent lab results (HbA1c, basic metabolic panel)
3. Attend a synchronous video consultation with a New York-licensed provider
4. Receive an electronic prescription sent directly to your preferred pharmacy
5. Complete any required prior authorization through the telehealth platform's support team

Telehealth visits for Trulicity in New York generally cost between $50 and $150 for the initial consultation if paying out of pocket. Many commercial insurance plans cover telehealth visits at the same copay tier as in-person visits under New York's telehealth parity law, which requires insurers to reimburse telehealth services on par with in-person equivalents.

Lab Requirements Before Starting Trulicity in New York

New York prescribers follow ADA-aligned protocols that require baseline labs before initiating any GLP-1 RA. You should expect the following tests.

Mandatory baseline labs:

• HbA1c (confirms type 2 diabetes diagnosis and establishes a treatment target; the ADA recommends an HbA1c goal of <7% for most adults)
• Fasting glucose or random glucose if HbA1c is unavailable
• Basic metabolic panel (BMP), including serum creatinine and eGFR, to rule out severe renal impairment
• Lipid panel (fasting or non-fasting), since GLP-1 RAs may modestly improve lipid profiles

Recommended additional labs:

• Thyroid function (TSH), given the boxed warning for medullary thyroid carcinoma risk in rodent studies
• Hepatic panel (ALT, AST), particularly if the patient takes concurrent hepatotoxic medications
• Amylase and lipase if the patient has a history of pancreatitis

Labs drawn within the prior 90 days are generally accepted by both in-person and telehealth prescribers. Quest Diagnostics and Labcorp operate hundreds of patient service centers across New York's five boroughs and upstate regions, making specimen collection straightforward. Some telehealth platforms offer at-home lab kits shipped to your door, with results returned in 3 to 5 business days.

Insurance Coverage and Prior Authorization in New York

Most paths to Trulicity in New York run through prior authorization. Understanding what your insurer requires saves weeks of delay.

New York Medicaid (managed care): Trulicity is covered for type 2 diabetes with prior authorization. The PA typically requires documented failure of or intolerance to metformin, a recent HbA1c value of 7% or higher, and a diagnosis code of E11.x (type 2 diabetes mellitus). New York Medicaid managed care organizations such as Healthfirst, Fidelis Care, and Molina each maintain their own formulary tiers, but dulaglutide appears on most preferred drug lists as a Tier 3 specialty medication.

Commercial insurance: Empire BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna plans sold in New York generally cover Trulicity at Tier 3 or Tier 4. According to Eli Lilly's savings card program, commercially insured patients may pay as little as $25 per month for up to 24 months, subject to annual caps.

Medicare Part D: Dulaglutide is covered under Part D formularies. After the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, Medicare beneficiaries in New York face substantially lower total annual costs for Trulicity than in prior years. A 2023 analysis published in JAMA Internal Medicine found that the IRA cap would reduce out-of-pocket spending on GLP-1 RAs by 30% to 60% for Part D enrollees.

Prior authorization documentation checklist:

• Current HbA1c result (dated within 90 days)
• Documentation of metformin trial (minimum 3 months at max tolerated dose, or documented contraindication/intolerance)
• Diagnosis code (E11.x for type 2 diabetes)
• Prescriber's clinical rationale for GLP-1 RA over alternative second-line agents
• Body weight and BMI (some plans require BMI documentation)

PA turnaround in New York averages 3 to 7 business days for commercial plans and 5 to 10 business days for Medicaid managed care. An expedited review (24 to 72 hours) can be requested when clinical urgency is documented, such as HbA1c above 10% or recurrent hypoglycemia on current therapy.

Where to Fill a Trulicity Prescription in New York

New York offers multiple pharmacy channels for Trulicity, each with different cost and convenience profiles.

Retail pharmacies: CVS, Walgreens, Rite Aid, and independent pharmacies across New York stock Trulicity. The drug requires refrigeration (36°F to 46°F), so verify that the pharmacy has adequate cold-chain storage. Retail pharmacies can typically fill a Trulicity prescription within 24 to 48 hours of PA approval.

Specialty pharmacies: Some insurers require Trulicity to be filled through designated specialty pharmacies such as CVS Specialty, Accredo (Express Scripts), or OptumRx Specialty. Specialty pharmacies offer medication counseling, refill reminders, and direct-to-patient shipping with cold-pack packaging.

Mail-order pharmacies: For 90-day supplies, mail-order pharmacies often provide the lowest per-unit cost. Patients in New York can receive Trulicity pens shipped in temperature-controlled packaging directly to their home. Major PBMs (CVS Caremark, Express Scripts, OptumRx) all support mail delivery within New York.

503A compounding pharmacies: New York's Board of Pharmacy permits 503A compounding pharmacies to compound medications pursuant to a valid patient-specific prescription. While dulaglutide itself is a biologic and cannot be compounded, 503A pharmacies in New York may compound other GLP-1-related supportive medications. The New York State Board of Pharmacy maintains strict oversight of compounding operations, requiring adherence to USP 795/797 standards.

Transferring a Trulicity Prescription to New York

Patients relocating to New York or splitting time between states can transfer an existing Trulicity prescription. The process depends on the original state and pharmacy system.

If your current pharmacy is part of a national chain (CVS, Walgreens), the transfer is often handled internally between locations. Call the New York location, provide your prescription number and date of birth, and the pharmacist will contact the originating store. Transfers within the same chain typically complete within 24 hours.

For independent-to-independent transfers, New York law requires the receiving pharmacist to verify the prescription directly with the transferring pharmacy. The original prescription must have remaining refills. New York does not accept prescriptions transferred from international pharmacies.

Telehealth patients switching to a New York-based provider will need a new prescription from a New York-licensed prescriber. Your prior labs, medical records, and prescription history speed this process considerably. Most telehealth platforms can issue a new prescription within one business day of a follow-up visit.

Dulaglutide Dosing and What to Expect in the First Month

The standard starting dose of Trulicity is 0.75 mg subcutaneously once weekly. The FDA-approved prescribing information recommends maintaining 0.75 mg for at least 4 weeks before considering escalation to 1.5 mg. If additional glycemic control is needed, the dose can be increased to 3.0 mg and then to the maximum of 4.5 mg at 4-week intervals.

The AWARD-11 trial (N=1,842) compared the 3.0 mg and 4.5 mg doses to 1.5 mg and found that the 4.5 mg dose reduced HbA1c by 1.87% from baseline versus 1.53% with 1.5 mg at 36 weeks. Weight loss was also dose-dependent: 4.5 mg produced a mean 4.7 kg reduction versus 3.1 kg with 1.5 mg.

Week 1 to 2 expectations: Mild nausea affects approximately 12% to 20% of patients in clinical trials. It typically peaks during the first 2 weeks and subsides by week 4 to 6. Eating smaller, more frequent meals and avoiding high-fat foods can reduce GI symptoms.

Week 3 to 4: Fasting glucose improvements often appear before HbA1c changes become measurable. Patients may notice reduced appetite. Your prescriber should check in (via telehealth or in-person) at the 4-week mark to assess tolerance and decide on dose escalation.

Injection technique: Trulicity's single-dose pen is designed for ease of use. The pen has a hidden, pre-attached needle, which reduces injection anxiety. Injection sites include the abdomen, thigh, or upper arm. Rotate sites weekly.

Cardiovascular and Renal Benefits Relevant to New York Patients

New York has among the highest rates of cardiovascular disease in the United States, driven partly by the prevalence of type 2 diabetes, hypertension, and obesity in the state's population. The cardiovascular benefits of dulaglutide are therefore particularly relevant for New York prescribers and patients.

The REWIND trial enrolled patients at a lower cardiovascular risk threshold than most GLP-1 RA outcome trials. Only 31% of participants had established cardiovascular disease at baseline. The primary composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group over a median 5.4 years. The Endocrine Society's 2022 clinical practice guideline cites REWIND as evidence supporting GLP-1 RA use in patients with type 2 diabetes and cardiovascular risk factors, even without established ASCVD.

A secondary analysis of REWIND published in The Lancet Diabetes & Endocrinology showed that dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained decline in eGFR of 30% or more, or chronic renal replacement therapy) by 15% (HR 0.85; 95% CI 0.77 to 0.93; P=0.0004). For New York patients with diabetic kidney disease, this renal benefit adds a meaningful layer to the clinical rationale for prescribing Trulicity.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in 2024: "GLP-1 receptor agonists like dulaglutide have moved from being purely glucose-lowering agents to drugs with demonstrated cardiovascular and renal protection, which is why our Standards of Care now position them early in the treatment algorithm for patients with cardiorenal risk."

Side Effects and Safety Monitoring

The most common adverse reactions in clinical trials were gastrointestinal: nausea (12.4%), diarrhea (8.9%), vomiting (6.0%), and abdominal pain (6.5%), according to the FDA prescribing label. These events are dose-dependent and generally diminish over time.

Trulicity carries a boxed warning for thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

New York prescribers should monitor:

• HbA1c every 3 months until stable, then every 6 months
• Renal function (eGFR, urine albumin-to-creatinine ratio) annually or more frequently if baseline impairment exists
• Signs of pancreatitis (persistent severe abdominal pain), which requires immediate discontinuation
• Injection site reactions, reported in 0.5% to 1% of trial participants

The ADA recommends reassessing GLP-1 RA therapy if the patient does not achieve at least a 0.5% HbA1c reduction within 3 to 6 months of reaching the target dose.

New York-Specific Patient Resources

The New York State Department of Health operates the Diabetes Prevention and Control Program, which connects residents with diabetes self-management education (DSME) programs across all 62 counties. DSME accreditation is granted by the CDC's Division of Diabetes Translation, and New York Medicaid covers DSME visits at no cost to the patient.

For uninsured patients, Eli Lilly's Lilly Cares Foundation provides Trulicity at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level. Application processing takes approximately 4 to 6 weeks. New York patients can also apply through the state's Essential Plan, which covers adults with incomes up to 200% FPL and includes prescription drug benefits.

Patients seeking a New York-licensed prescriber for Trulicity can begin with a telehealth consultation or contact their primary care physician for a referral to an endocrinologist. The Endocrine Society's physician finder lists board-certified endocrinologists by ZIP code.